Related Experiment Video

Updated: Jul 13, 2026

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Perspectives on the development of a therapeutic HER-2 cancer vaccine

Valéry Renard1, Dana R Leach

  • 1Pharmexa A/S, Kogle Allé 6, DK-2970 Hørsholm, Denmark. vr@pharmexa.com

Vaccine
|July 17, 2007
PubMed

Insights

This study explores a novel protein vaccine targeting HER-2/neu for breast cancer. The vaccine aims to induce humoral immune responses, showing promise in preclinical and clinical evaluations.

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • Most cancer vaccines focus on cytotoxic T-lymphocyte (CTL) responses.
  • Monoclonal antibodies targeting HER-2/neu, CD20, EGFR, and VEGF show clinical success.
  • This suggests humoral immune responses are also crucial for anti-tumour immunity.

Purpose of the Study:

  • To develop a protein vaccine targeting HER-2/neu.
  • To evaluate the vaccine's immunogenicity and safety in preclinical and clinical settings.
  • To assess the potential of a humoral immune response against HER-2/neu in cancer therapy.

Main Methods:

  • Development of a protein vaccine targeting HER-2/neu.
  • Preclinical testing in animal models for immunologic and toxicologic assessment.
  • Evaluation in three clinical trials involving breast cancer patients.

Main Results:

  • The vaccine's development and testing are detailed.
  • Immunologic results from animal models and toxicology programs are presented.
  • Clinical trial data from breast cancer patients are included.

Conclusions:

  • HER-2/neu is a relevant target for cancer vaccines inducing humoral responses.
  • The protein vaccine shows potential for mimicking or improving monoclonal antibody therapies.
  • Further evaluation in clinical trials is warranted for breast cancer treatment.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...